Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy - PubMed

Review

Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy

Dharmesh A Patel et al. Bioorg Chem. 2024 Feb.

Abstract

One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors.

Keywords: Anticancer; Antiproliferative activity; CDK2 enzyme; CDK2 inhibitor; Cell cycle arrest.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

• Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.

  Coppock DL, Buffolino P, Kopman C, Nathanson L. Coppock DL, et al. Exp Cell Res. 1995 Nov;221(1):92-102. doi: 10.1006/excr.1995.1356. Exp Cell Res. 1995. PMID: 7589260

• Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.

  Yin MB, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK, Rustum YM. Yin MB, et al. Exp Cell Res. 1999 Feb 25;247(1):189-99. doi: 10.1006/excr.1998.4346. Exp Cell Res. 1999. PMID: 10047461

• CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.

  Morris TA, DeLorenzo RJ, Tombes RM. Morris TA, et al. Exp Cell Res. 1998 May 1;240(2):218-27. doi: 10.1006/excr.1997.3925. Exp Cell Res. 1998. PMID: 9596994

• [The characterization of human cdc2 kinase and CDK2].

  Yasuda H, Kamijo M, Ohba Y. Yasuda H, et al. Yakugaku Zasshi. 1993 Dec;113(12):829-46. doi: 10.1248/yakushi1947.113.12_829. Yakugaku Zasshi. 1993. PMID: 8301538 Review. Japanese.

• Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

  Johnson LN, De Moliner E, Brown NR, Song H, Barford D, Endicott JA, Noble ME. Johnson LN, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):113-24. doi: 10.1016/s0163-7258(02)00181-x. Pharmacol Ther. 2002. PMID: 12191604 Review.

Cited by

• Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond.

  Kargbo RB. Kargbo RB. ACS Med Chem Lett. 2024 Jun 24;15(7):1004-1006. doi: 10.1021/acsmedchemlett.4c00265. eCollection 2024 Jul 11. ACS Med Chem Lett. 2024. PMID: 39015280

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Miscellaneous

  • NCI CPTAC Assay Portal